Bevacizumab, the first and most studied anti-VEGF agent, when used as maintenance therapy following surgical debulking and first-line chemotherapy, led to significant improvements in the progression-free survival of patients with ovarian cancer but did not have an impact on the survival. The gene discussed is VEGFA; the disease is ovarian cancer.